Carolyn R. Bertozzi
Known title: DirectorCIK: 0001698766
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Transaction History
| OABI | ▲ Buy | Option Exercise | 20,000 | — | 6/17/2026 | View on chart |
| OABI | ▲ Buy | Option Exercise | 17,769 | — | 11/1/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 20,000 | — | 6/17/2025 | View on chart |
| ALNY | ▲ Buy | Grant | 775 | $0 | 5/8/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 17,769 | — | 11/1/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 20,000 | — | 6/18/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 17,770 | — | 11/1/2023 | View on chart |
| OABI | ▲ Buy | Grant | 53,308 | $0 | 1/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
OmniAb (OABI) Shares Analyst/Investor Day Slideshow
OmniAb released a slideshow from its recent Analyst/Investor Day on Seeking Alpha. The presentation offered updates on the company's pipeline and strategic plans. The material provides investors with additional detail that may influence expectations, especially as the stock trades near its recent support level of $1.48 and below the average analyst target of $8.40.
OmniAb (OABI) Shares Analyst/Investor Day Slideshow. OmniAb released a slideshow from its recent Analyst/Investor Day on Seeking Alpha. The presentation offered updates on the company's pipeline and strategic plans. The material provides investors with additional detail that may influence expectations, especially as the stock trades near its recent support level of $1.48 and below the average analyst target of $8.40.